J 2002

Endothelin-1 gene polymorphism in the identification of patients at risk for malignant ventricular arrhythmia

KOZÁK, Milan, Lydie IZAKOVIČOVÁ HOLLÁ, Lubomír KŘIVAN, Anna VAŠKŮ, Milan SEPŠI et. al.

Základní údaje

Originální název

Endothelin-1 gene polymorphism in the identification of patients at risk for malignant ventricular arrhythmia

Autoři

KOZÁK, Milan (203 Česká republika, garant), Lydie IZAKOVIČOVÁ HOLLÁ (203 Česká republika), Lubomír KŘIVAN (203 Česká republika), Anna VAŠKŮ (203 Česká republika), Milan SEPŠI (203 Česká republika), Bořivoj SEMRÁD (203 Česká republika) a Jiří VÁCHA (203 Česká republika)

Vydání

Medical Science Monitor (International Medical Journal of Experimental and Clinical Research), USA, International Scientific Literature, Inc, 2002, 1234-1010

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/02:00007238

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

gene; endothelin; polymorphism; ET-1; arrhythmia; defibrillator
Změněno: 13. 5. 2003 15:03, prof. MUDr. Lydie Izakovičová Hollá, Ph.D.

Anotace

V originále

The endothelins are peptides with vasoconstriction and growth-promoting properties. Endothelin-1 (ET-1) is known for its direct positive inotropic and chronotropic effects on isolated heart, and for growth effects. The aim of this pilot study was to investigate the frequency distribution of a common polymorphism of the endothelin gene and its possible relation to the hemodynamic consequences of malignant ventricular arrhythmia in patients with structural heart disease. We studied 26 consecutive patients with malignant ventricular arrhythmia and implantable cardioverter defibrillators (ICD), mean age 62.7 years, mean LVEF 0.37. The Taq polymorphism of ET-1 was detected using our original PCR method. Out of the 26 patients, 9 (34%) had reccurent palpitations and 8 (30.8%) had syncopes during their malignant arrhythmic episodes. 19 of the patients were receiving amiodarone after ICD implantation, 7 were not. 15 patients had the (++) and 11 had (+-) ET-1 genotype, none had the (--) genotype. The risk of syncopes was associated with the (++) genotype (p=0.01). Patients with amiodarone had a significantly higher frequency of the (++) genotype (p=0.011). All our results suggested that the presence of the (++) ET-1 genotype in patients with structural heart disease, severe left ventricular dysfunction, and malignant ventricular arrhythmia put these patients at a higher risk of hemodynamic collapse during arrhythmic episodes.

Návaznosti

MSM 141100002, záměr
Název: Molekulární patofyziologie multigenních chorob
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Molekulární patofyziologie multigenních chorob